Design Space Approach for Pharmaceutical Tablet Development

被引:21
作者
Chatzizacharia, Kalliopi A. [1 ]
Hatziavramidis, Dimitris T. [1 ]
机构
[1] Natl Tech Univ Athens, Sch Chem Engn, Athens 15780, Greece
关键词
OPTIMIZATION; GRANULATION;
D O I
10.1021/ie5005652
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
Methodologies to determine the Design Space of a pharmaceutical product, within which continuous improvement can be implemented and postapproval changes in material attributes and process parameters can be introduced without prior approval, are presented. The type of methodology used depends on the type of experimental data obtained for the purpose of determining the Design Space. However, when one is unsure about the data collected to determine the Design Space, one can determine the quality of the data from successive application of the various methods and evaluation of the desirability measure for each method. The Design Spaces for a two- and three-process tablet manufacturing are determined by Response Surface Method (RSM), Bayesian Post Predictive Approach (BPPA), and Artificial Neural Networks (ANN), based on local or global specification limits of the response variables provided by multiresponse optimization and overlapping responses, respectively. The Response Surface Method is the most effective of these methods in determining the Design Spaces for the aforementioned data sets, confirming that the particular data are complete and lack uncertainty or structure, the specific features that the Bayesian Post Predictive Approach and Artificial Neural Networks methods are suited to address, respectively.
引用
收藏
页码:12003 / 12009
页数:7
相关论文
共 19 条
[1]  
[Anonymous], 2009, GUID Q8 R2 NOT GUID
[2]   Design Space of Pharmaceutical Processes Using Data-Driven-Based Methods [J].
Boukouvala, Fani ;
Muzzio, Fernando J. ;
Ierapetritou, Marianthi G. .
JOURNAL OF PHARMACEUTICAL INNOVATION, 2010, 5 (03) :119-137
[3]  
Garcia T., 2008, Journal of Pharmaceutical Innovation, V3, P60, DOI DOI 10.1007/S12247-008-9032-4
[4]  
Harrington E.C., 1965, Industrial Quality Control, V21, P494, DOI DOI 10.1128/AM.13.3.494-495.1965
[5]  
Hayashi Y., 2012, J PHARM SCI, V101, P2
[6]   Quality by design case study: An integrated multivariate approach to drug product and process development [J].
Huang, Jun ;
Kaul, Goldi ;
Cai, Chunsheng ;
Chatlapalli, Ramarao ;
Hernandez-Abad, Pedro ;
Ghosh, Krishnendu ;
Nagi, Arwinder .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 382 (1-2) :23-32
[7]   RETRACTED: ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL PRODUCT FORMULATION: NEURAL COMPUTING (Retracted article. See vol. 17, pg. 543, 2011) [J].
Ibric, Svetlana ;
Djuric, Zorica ;
Parojcic, Jelena ;
Petrovic, Jelena .
CHEMICAL INDUSTRY & CHEMICAL ENGINEERING QUARTERLY, 2009, 15 (04) :227-236
[8]   Advantages of neurofuzzy logic against conventional experimental design and statistical analysis in studying and developing direct compression formulations [J].
Landin, Mariana ;
Rowe, R. C. ;
York, P. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 38 (04) :325-331
[9]  
Lee M.S., 2007, QUALITY TECHNOLOGY Q, V4, P365
[10]  
Lepore J., 2008, Journal of Pharmaceutical Innovation, V3, P79, DOI DOI 10.1007/S12247-008-9034-2